In a much welcome medical development, the Food and Drug Administration has given the nod to use of Istodax, a drug from the house of Gloucester Pharmaceuticals, for treatment of Cutaneous T-cell lymphoma (CTCL).

As confirmed by the drug manufacturer in an official statement, the drug has been approved for use in people who have tried at least one systemic therapy before. A cancer of the germs fighting lymphatic system, CTCL involves growth of cancerous cells of the skin that can cause patches which are disfigured and itch badly.